Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q13394
UPID:
MB211_HUMAN
Alternative names:
Protein mab-21-like 1
Alternative UPACC:
Q13394; Q6I9T5
Background:
Putative nucleotidyltransferase MAB21L1, also known as Protein mab-21-like 1, plays a crucial role in embryonic development, particularly in the normal development of the eye. Its ability to bind single-stranded RNA underscores its significance in cellular processes, although its nucleotidyltransferase activity in vivo remains to be fully elucidated.
Therapeutic significance:
MAB21L1 is implicated in Cerebellar, ocular, craniofacial, and genital syndrome, a condition marked by developmental delays, cerebellar hypoplasia, and various physical anomalies. Understanding the role of MAB21L1 could open doors to potential therapeutic strategies for this syndrome.